Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients 18-80 years of age with active RA;~* patients who participated in MabThera study WA17042, and completed to at least the Week 24 visit;~* eligible for re-treatment, based on clinical symptoms;~* patients of reproductive potential must be using reliable contraceptive methods.~Exclusion Criteria:~* patients who participated in MabThera study WA17042 but withdrew into the safety follow-up;~* current treatment with any other disease-modifying antirheumatic drug (apart from methotrexate), or any anti-TNFalfa, anti-IL1, or other biologic therapies;~* development of any new contraindications to receiving MabThera;~* women who are pregnant or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- MabThera/Rituxan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).